PMID- 36524255
OWN - NLM
STAT- MEDLINE
DCOM- 20221219
LR  - 20221222
IS  - 1938-2723 (Electronic)
IS  - 1076-0296 (Print)
IS  - 1076-0296 (Linking)
VI  - 28
DP  - 2022 Jan-Dec
TI  - Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing 
      Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) 
      Registry.
PG  - 10760296221123306
LID - 10.1177/10760296221123306 [doi]
LID - 10760296221123306
AB  - BACKGROUND: Direct oral anticoagulants (DOACs) have increasingly become an 
      alternative to warfarin in atrial fibrillation (AF) patients. Nonetheless, data 
      on the effectiveness and safety of DOACs in periprocedural of catheter ablation 
      (CA) in real-world practice was relatively rare. METHODS AND RESULTS: 3385 AF 
      patients underwent initial CA and never used oral anticoagulant before enrollment 
      between April 2013 and December 2018 were involved from China Atrial Fibrillation 
      (China-AF) Registry. Warfarin, rivaroxaban and dabigatran were used in 1896 
      (56.0%), 718 (21.2%), and 771 (22.8%) patients, respectively. Propensity score 
      matching was used to balance covariates across study groups. No significant 
      differences were observed in rivaroxaban-warfarin, dabigatran-warfarin and 
      dabigatran-rivaroxaban cohort for thromboembolic (TE) and major bleeding (MB) 
      incidence. Similar results were also revealed in low-dose rivaroxaban 
      (R(LD))-warfarin, low-dose dabigatran (D(LD))-warfarin and D(LD)-R(LD) cohort. 
      However, the risk of non-MB was higher not only on standard-dose of rivaroxaban 
      but also on R(LD) when compared with warfarin and with D(LD), respectively. 
      CONCLUSIONS: In this study, the incidence of TE and MB were both comparable in 
      standard- or low-dose DOACs versus warfarin and between the two DOACs, whereas 
      the risk of non-MB was higher in rivaroxaban than in warfarin and in R(LD) than 
      in D(LD).
FAU - Dong, Zhimin
AU  - Dong Z
AUID- ORCID: 0000-0002-7105-2364
AD  - Department of Cardiology, 12667Beijing Anzhen Hospital, Capital Medical 
      University, National Clinical Research Center for Cardiovascular Diseases, 
      Beijing, China.
AD  - Cardiovascular Center, 117902Beijing Tongren Hospital, Capital Medical 
      University, Beijing, China.
FAU - Hou, Xiaoxia
AU  - Hou X
AD  - Cardiovascular Center, 117902Beijing Tongren Hospital, Capital Medical 
      University, Beijing, China.
FAU - Du, Xin
AU  - Du X
AD  - Department of Cardiology, 12667Beijing Anzhen Hospital, Capital Medical 
      University, National Clinical Research Center for Cardiovascular Diseases, 
      Beijing, China.
FAU - He, Liu
AU  - He L
AD  - Department of Cardiology, 12667Beijing Anzhen Hospital, Capital Medical 
      University, National Clinical Research Center for Cardiovascular Diseases, 
      Beijing, China.
FAU - Dong, Jianzeng
AU  - Dong J
AD  - Department of Cardiology, 12667Beijing Anzhen Hospital, Capital Medical 
      University, National Clinical Research Center for Cardiovascular Diseases, 
      Beijing, China.
AD  - Department of Cardiology, 191599The First Affiliated Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Ma, Changsheng
AU  - Ma C
AD  - Department of Cardiology, 12667Beijing Anzhen Hospital, Capital Medical 
      University, National Clinical Research Center for Cardiovascular Diseases, 
      Beijing, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Appl Thromb Hemost
JT  - Clinical and applied thrombosis/hemostasis : official journal of the 
      International Academy of Clinical and Applied Thrombosis/Hemostasis
JID - 9508125
RN  - 5Q7ZVV76EI (Warfarin)
RN  - I0VM4M70GC (Dabigatran)
RN  - 9NDF7JZ4M3 (Rivaroxaban)
RN  - 0 (Pyridones)
RN  - 0 (Pyrazoles)
RN  - 0 (Anticoagulants)
SB  - IM
MH  - Humans
MH  - *Atrial Fibrillation/drug therapy/surgery/epidemiology
MH  - Warfarin/adverse effects
MH  - Dabigatran/adverse effects
MH  - Rivaroxaban/adverse effects
MH  - Pyridones/therapeutic use
MH  - Pyrazoles/therapeutic use
MH  - Treatment Outcome
MH  - Anticoagulants/adverse effects
MH  - *Catheter Ablation/adverse effects
MH  - Hemorrhage/drug therapy
MH  - *Thromboembolism/etiology/prevention & control/drug therapy
MH  - Registries
MH  - Administration, Oral
PMC - PMC9761217
OTO - NOTNLM
OT  - anticoagulants
OT  - atrial fibrillation
OT  - catheter ablation
OT  - direct oral anticoagulants
OT  - warfarin
COIS- Changsheng Ma has received honoraria from Bristol-Myers Squibb, Pfizer, Johnson & 
      Johnson, Boehringer-Ingelheim and Bayer for giving lectures. Jianzeng Dong has 
      received honoraria from Johnson & Johnson for giving lectures. The other authors 
      have no disclosures.
EDAT- 2022/12/17 06:00
MHDA- 2022/12/20 06:00
PMCR- 2022/12/15
CRDT- 2022/12/16 02:39
PHST- 2022/12/16 02:39 [entrez]
PHST- 2022/12/17 06:00 [pubmed]
PHST- 2022/12/20 06:00 [medline]
PHST- 2022/12/15 00:00 [pmc-release]
AID - 10.1177_10760296221123306 [pii]
AID - 10.1177/10760296221123306 [doi]
PST - ppublish
SO  - Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221123306. doi: 
      10.1177/10760296221123306.